Urban Kosak

Ljubljana, 1000, Slovenia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors.

Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors.

Journal: Journal of medicinal chemistry

Published: August 08, 2025

Transforming ureas into carbamates: From allosteric p38α MAPK ligands to dual BChE/p38α MAPK inhibitors.

Transforming ureas into carbamates: From allosteric p38α MAPK ligands to dual BChE/p38α MAPK inhibitors.

Journal: Bioorganic chemistry

Published: July 14, 2025

N-Propargylpyrrolidine-based butyrylcholinesterase and monoamine oxidase inhibitors.

N-Propargylpyrrolidine-based butyrylcholinesterase and monoamine oxidase inhibitors.

Journal: Chemico-biological interactions

Published: June 30, 2025

Lead Optimization of a Butyrylcholinesterase Inhibitor for the Treatment of Alzheimer's Disease.

Lead Optimization of a Butyrylcholinesterase Inhibitor for the Treatment of Alzheimer's Disease.

Journal: Journal of medicinal chemistry

Published: June 02, 2025

Chiral switch of a butyrylcholinesterase inhibitor for the treatment of Alzheimer's disease.

Chiral switch of a butyrylcholinesterase inhibitor for the treatment of Alzheimer's disease.

Journal: Chemico-biological interactions

Published: May 23, 2025

A novel butyrylcholinesterase inhibitor induces antidepressant, pro-cognitive, and anti-anhedonic effects in Flinders Sensitive Line rats: The role of the ghrelin-dopamine cascade.

A novel butyrylcholinesterase inhibitor induces antidepressant, pro-cognitive, and anti-anhedonic effects in Flinders Sensitive Line rats: The role of the ghrelin-dopamine cascade.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: March 03, 2025

Dual inhibition of butyrylcholinesterase and p38α mitogen-activated protein kinase: A new approach for the treatment of Alzheimer's disease.

Dual inhibition of butyrylcholinesterase and p38α mitogen-activated protein kinase: A new approach for the treatment of Alzheimer's disease.

Journal: Pharmacology & therapeutics

Published: July 02, 2024

Repurposing of 8-Hydroxyquinoline-Based Butyrylcholinesterase and Cathepsin B Ligands as Potent Nonpeptidic Deoxyribonuclease I Inhibitors.

Repurposing of 8-Hydroxyquinoline-Based Butyrylcholinesterase and Cathepsin B Ligands as Potent Nonpeptidic Deoxyribonuclease I Inhibitors.

Journal: ChemMedChem

Published: November 03, 2021

Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor.

Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor.

Journal: Scientific reports

Published: December 15, 2020

Longitudinal evaluation of a novel BChE PET tracer as an early in vivo biomarker in the brain of a mouse model for Alzheimer disease.

Longitudinal evaluation of a novel BChE PET tracer as an early in vivo biomarker in the brain of a mouse model for Alzheimer disease.

Journal: Theranostics

Published: October 16, 2020

Synthesis and Initial Characterization of a Reversible, Selective 18F-Labeled Radiotracer for Human Butyrylcholinesterase.

Synthesis and Initial Characterization of a Reversible, Selective 18F-Labeled Radiotracer for Human Butyrylcholinesterase.

Journal: Molecular imaging and biology

Published: October 06, 2020

N-alkylpiperidine carbamates as potential anti-Alzheimer's agents.

N-alkylpiperidine carbamates as potential anti-Alzheimer's agents.

Journal: European journal of medicinal chemistry

Published: February 27, 2020

Showing 1-12 of 18

Last Updated: 09/26/2026